Repositioning imatinib for spinal cord injury

Neural Regeneration Research

Volumn 10, Issue 10, 2015, Pages 1591-1593

  Kjell, Jacob ^a,b   Olson, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; EPOTHILONE B; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN S 100; RILUZOLE;

BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); EXCITOTOXICITY; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEUKEMIA; MACROPHAGE ACTIVATION; MASTOCYTOSIS; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SPINAL CORD INJURY;

EID: 84945536772     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.167751     Document Type: Note

References (11)

1. Abrams MB, Nilsson I, Lewandowski SA, Kjell J, Codeluppi S, Olson L, Eriksson U (2012) Imatinib enhances functional outcome after spinal cord injury. PLoS One 7:e38760.
2. Adzemovic M, Zeitelhofer M, Eriksson U, Olsson T, Nilsson I (2013) Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One 8:e56586.
3. Angeli CA, Edgerton VR, Gerasimenko YP, Harkema SJ (2014) Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans. Brain 137:1394-1409.
4. Fehlings MG, Nakashima H, Nagoshi N, Chow DSL, Grossman RG, Kopjar B (2015) Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double- blinded, placebo-controlled parallel multi-center trial. Spinal Cord doi: 10.1038/sc.2015.95.
5. Figley SA, Khosravi R, Legasto JM, Tseng Y-F, Fehlings MG (2014) Characterization of vascular disruption and blood-spinal cord barrierp ermeability following traumatic spinal cord injury. J Neurotrauma 31:541-552.
6. Göritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisén J (2011) A pericyte origin of spinal cord scar tissue. Science 333:238-242.
7. Hayashi Y, Nakamae H, Katayama T, Nakane T, Koh H, Nakamae M, Hirose A, Hagihara K, Terada Y, Nakao Y, Hino M (2012) Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma 53:1084-1089.
8. Kjell J, Finn A, Hao J, Wellfet K, Josephson A, Svensson CI, Wiesenfeld- Hallin Z, Eriksson U, Abrams MB, Olson L (2015) Delayed imatinib treatment for acute spinal cord injury; functional recovery and serum biomarkers. J Neurotrauma doi:10.1089/neu.2014.3863.
9. Popovich PG, Horner PJ, Mullin BB, Stokes BT (1996) A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp Neurol 142:258-275.
10. Ruschel J, Hellal F, Flynn KC, Dupraz S, Elliott DA, Tedeschi A, Bates M, Sliwinski C, Brook G, Dobrindt K, Peitz M, Brüstle O, Norenberg MD, Blesch A, Weidner N, Bunge MB, Bixby JL, Bradke F (2015) Axonal regeneration. Systemic administration of epothilone B promotes axon regeneration after spinal cord injury. Science 348:347-352.
11. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14:731-737.